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Background. Retroperitoneal sarcomas (RPS) comprise approximately 15% of all soft-tissue sarcomas and frequently associated
with signiﬁcant morbidity and as little as 30% 5-year survival. Here, we provide a large, contemporary, and multi-institutional
experience to determine which tumor, patient, and treatment characteristics are associated with long-term outcomes in RPS.
Methods. 571 patients with primary RPS were identiﬁed from the United States Sarcoma Collaboration (USSC). RPS patients who
underwent resection from January 2000 to April 2016 were included with patient, tumor, and treatment-speciﬁc variables
investigated as independent predictors of survival. Survival analyses for disease-free and overall survival were conducted using
Kaplan–Meier and Cox proportional hazards model methods. Results. .e study cohort was 55% female, with a median age of
58.9 years (IQR: 48.6–70.0). .e most common tumor histiotypes were liposarcoma (34%) and leiomyosarcoma (28%). Median
follow-up was 30.6months (IQR: 11.2–60.4). Median disease-free survival was 35.3months (95% CI: 27.6–43.0), with multivariate
predictors of poorer disease-free survival including higher grade tumors, nodal-positive disease, and multivisceral resection.
Median overall survival was 81.6months (95% CI: 66.3–96.8). Multivariate predictors of shorter overall survival included higher
grade tumors, nodal-positive and multifocal disease, systemic chemotherapy, and grossly positive margins (R2) following re-
section. Conclusions. .e strongest predictors of disease-free and overall survival are tumor-speciﬁc characteristics, while surgical
factors are less impactful. Nonsurgical therapies are not associated with improved outcomes despite persistent interest and
utilization. Complete macroscopic resection (R0/R1) remains a persistent potentially modiﬁable risk factor associated with
improved overall survival in patients with retroperitoneal sarcomas.
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1. Introduction
Sarcomas are tumors of mesenchymal origin and represent
only approximately 1% of all cancers in the adults. .ese
tumors are most commonly found in the extremity; how-
ever, they are retroperitoneal in 15% of cases [1]. Despite
their rarity, sarcomas represent a vast array of tumor his-
tiotypes, currently with 60 identiﬁed subtypes, with be-
havioral diﬀerences making study and generalizations about
their care diﬃcult [2].
Retroperitoneal sarcomas (RPS) in particular, due to
their location, tend to be asymptomatic and appear at late
stages and with historically poor outcomes; the average
tumor size at diagnosis can be up to 15–20 cm [3]. .e rarity
of these tumors and number of histiotypes have led to recent
attempts to consolidate investigative eﬀorts between in-
stitutions, such as with the Transatlantic RPS Working
Group (TAWG), Surveillance, Epidemiology, and End Re-
sults (SEER), and the National Cancer Database (NCDB)
[4–6].
Previous studies report that the strongest and most
consistent predictor of either disease-free or overall survival
is tumor grade [7, 8]. Larger tumor size, although variably
deﬁned, has also been shown to be predictive of worse
survival outcomes [4, 5]. Furthermore, margin status ap-
pears to contribute to long-term outcomes as gross residual
disease following resection has been associated with survival
similar to unresectable disease (though some suggest long-
term survival can be achieved with a R2 resection in select
circumstances with favorable histological subtypes) [9–11].
And ﬁnally, the utility of chemotherapy or radiotherapy in
RPS continues to be poorly understood (TAWG). .e im-
portance of nonsurgical therapies remains an active focus of
investigation, with a recent study suggesting possible overall
survival beneﬁt with administration of radiation therapy and
recent European trials showing beneﬁts to epirubicin- and
ifosfamide-based chemotherapy regimens for soft-tissue
extremity and truncal sarcomas [12, 13]. Finally, the use
of histologically target-based chemotherapies has increased
and continues to be an ongoing and active area of research
[14].
Using a contemporary database with granular histo-
pathologic data, the purpose of this investigation was to
identify factors associated with recurrence-free survival and
overall survival in patients with retroperitoneal sarcomas.
Our primary aim was to discern whether any modiﬁable
pre-, intra-, or postoperative patient-, provider-, or tumor-
speciﬁc characteristics could be identiﬁed. Additionally, we
sought to determine if trends in increasing use of chemo-
therapy and radiotherapy had any eﬀect on outcomes. .e
granularity of the histopathologic data from the USSC da-
tabase in conjunction with its size makes it poised to add to
the growing body of the literature attempting to identify
factors which predict worse survival.
2. Methods
2.1. Patient Population. .e study cohort was derived from
the United States Sarcoma Collaboration (USSC) database,
created from the following tertiary centres: University of
Wisconsin, Emory University, Stanford University, Medical
College of Wisconsin, Wake Forest University, the Ohio
State University, University of Chicago Medicine, and
Washington University. A total of 571 patients with primary
retroperitoneal sarcomas (RPS) treated between January
2000 and April 2016 was included. Only primary RPS were
considered, with recurrent tumors excluded. All patients
underwent resection, and follow-up was recorded in
months. Histologic diagnosis was conﬁrmed, and grade was
assigned as either low grade (Federation Nationale des
Centres de Lutte Contre le Cancer (FNCLCC)�G1), high
grade (FNCLCC�G2 or G3), or unable to be assessed
(FNCLCC�GX) according to the FNCLCC or TNM two-
tier grading schema [15, 16].
In this retrospective cohort analysis, independent vari-
ables included age, sex, smoking status, prior radiation
exposure, genetic syndromes, tumor size, nodal disease,
multifocal disease, number of organs included in an en bloc
resection, receipt of neo- or adjuvant chemotherapy/
radiation, and postoperative margin status. Primary out-
comes of interest were disease-free survival and overall
survival. Secondary outcomes were trends of survival over
time. Recurrence was deﬁned as either pathologic or ra-
diographic evidence of recurrence following resection, in
months. Overall survival was deﬁned as the length of time
between surgery and death from any cause with time cen-
sored at last follow-up.
2.2. Statistical Analysis. All continuous variables were re-
ported as median values with an associated interquartile
range. All categorical variables were reported as a percentage
of the total. Categorical comparisons were made using chi-
squared test or Fisher’s exact test (FET) as appropriate.
Univariate Kaplan–Meier analysis using logrank testing and
subsequent multivariate analysis utilizing Cox proportional
hazards ratios were derived for the outcomes of interest. All
p values <0.05 were considered signiﬁcant in univariate
analysis and thus included in multivariate analyses. All
p values <0.05 in multivariate analyses were considered
signiﬁcant. Univariate subanalysis was performed to de-
termine if diﬀerences existed between tumor histiotype and
recurrence-free survival and overall survival and locore-
gional versus distant recurrence. Additional multivariate
logistical regression was performed, where appropriate, on
selected subanalysis thought to not replicate prior analyses.
Multivariate logistical regression analysis was performed in a
similar fashion to the Cox proportional hazards analysis. All
data were stored using Excel (Microsoft Corporation,
Redmond, WA), and all statistical analysis was performed
using SPSS 24 (IBM Corporation, Armonk, NY). Appro-
priate IRB approval was obtained from each institution.
3. Results
3.1. Patient Demographics. .e study population was 45%
male and predominantly white (72%). Median BMI was 27
(IQR: 27.0–31.7). Median age was 58.9 (interquartile range
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(IQR): 48.6–70.0), with other demographics outlined in
Table 1. Median follow-up was 30.6months (IQR: 11.2–
60.4). .ree percent of patients had a known genetic syn-
drome, including NF1, Li–Fraumeni, and FAP.
.e most common tumor histiotype was liposarcoma
(34%), followed by leiomyosarcoma (28%), and sarcoma not
otherwise speciﬁed (5%); “others” comprised 33% of the
study population (Figure 1). Most tumors were high grade
by either the FNCLCC or TNM two-tier grading system
(57%). Only 4% of tumors were nodal-positive (N1 disease),
and 3% were multifocal. .e median tumor size was 13.9 cm
(IQR: 8.2–21.0). Resections typically included en bloc re-
section of 1-2 organs (55%), most commonly left colon
(27%), left kidney (23%), or small bowel (27%). A small
proportion of patients were treated with radiation therapy
(8%), chemotherapy (3%), or both radiation and chemo-
therapy (19%). .e majority of resections were R0 (57%);
however, R1 and R2 resections occurred in 32% and 8% of
cases, respectively.
3.2. Disease-Free Survival. Median disease-free survival was
35.3months (95% CI: 27.6–43.0) (Figure 2). Univariate
analysis showed tumor grade, nodal status, tumor size,
number of organ resected, and margin status to be signif-
icantly associated (p< 0.05) with disease-free survival. Of
these, high-grade tumors (p< 0.01; HR: 2.66, 95% CI:
1.88–3.77), nodal-positive disease (N1) (p< 0.01; HR: 2.08,
95% CI: 1.22–3.52), and larger en bloc resections (3-4 or-
gans) (p � 0.04; HR: 1.56, 95% CI: 1.03–2.37) were found to
be independent predictors of disease-free survival on mul-
tivariate Cox proportional hazards analysis (Figure 3).
3.3. Overall Survival. Median overall survival was
81.6months (95% CI: 66.3–96.8) (Figure 2). On univariate
analysis, as shown in Figure 4, age greater than 65, tumor
grade, nodal status, presence of multifocal disease, number
of organs resected, receipt of additional therapies, and
margin status were signiﬁcantly associated (p< 0.05) with
overall survival. Of these, multivariate Cox proportional
hazards demonstrated that age greater than 65 (p � 0.03;
HR: 1.38, 95% CI: 1.03–1.84), high-grade tumors (p< 0.01;
HR: 2.44, 95% CI: 1.60–3.74), nodal-positive disease (N1)
(p< 0.01; HR: 2.59, 95% CI: 1.52–4.40), systemic chemo-
therapy (p< 0.01; HR: 2.65, 95% CI: 1.40–4.99), multifocal
disease (p< 0.01; HR: 2.43, 95% CI: 1.25–4.69), and grossly
positive margins (R2) (p< 0.01; HR: 2.41, 95% CI: 1.57–3.69)
were found to be independently associated with worse
survival.
3.4. Temporal Subanalysis. Disease-free survival and overall
survival were compared across time to determine if diﬀer-
ences in survival existed between diﬀerent periods of
treatment using 3-year bins (e.g., 2000–2003) examining 1-
year outcome. No diﬀerences were found for either disease-
Table 1: Demographic and tumoral data for all patients included in
the study.
Demographic/tumor characteristic N (%)
Age >65
Yes 196 (34)
No 375 (66)
Sex
Male 255 (45)
Female 316 (55)
Race
White 411 (72)
African American 69 (12)
Others/unknown 91 (16)
BMI≥30 141 (25)<30 430 (75)
Smoking status
Yes 496 (87)
No 75 (13)
Prior radiation exposure
Yes 35 (6)
No 536 (94)
Known genetic syndrome
Yes 556 (97)
No 15 (3)
Histology
Leiomyosarcoma 162 (28)
Liposarcoma 196 (34)
Sarcoma NOS 26 (5)
Other sarcomas 187 (33)
Grade
Low grade 131 (23)
High grade 326 (57)
Nodal disease
N0 549 (96)
N1 22 (4)
Multifocal disease
Yes 17 (3)
No 554 (97)
Size of tumor<10 cm 201 (35)
10–20 cm 217 (38)>20 cm 145 (25)
Organs resected
0 140 (25)
1-2 315 (55)
3-4 82 (14)≥5 34 (6)
.erapies
No therapy 396 (70)
Radiation therapy 45 (8)
Chemotherapy 19 (3)
Radiation and chemotherapy 111 (19)
Margin status
R0 328 (57)
R1 184 (32)
R2 45 (8)
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free survival (p � 0.37) or overall survival (p � 0.19) for 1-
year outcome on Chi-squared analysis.
3.5. Recurrence Pattern Subanalysis. Recurrence was ana-
lyzed by site, including distant, locoregional, or both, for the
237 patients for which data were available. For this cohort,
median recurrence-free survival was 23.7months. Median
recurrence-free survival was found to be signiﬁcantly dif-
ferent (p � 0.02), with locoregional recurrence at 25.4
months (95% CI: 14.6–36.2), distant recurrence at 16.4
months (95% CI: 10.4–22.4), and both locoregional and
distant recurrence at 36.4months (95% CI: 23.7–49.1). Chi-
squared analysis demonstrated no diﬀerences in recurrence
patterns (locoregional versus distant recurrence versus both)
and use of adjuvant radiotherapy (p � 0.67), neoadjuvant
radiotherapy (p � 0.17), neoadjuvant chemotherapy
(p � 0.16), or adjuvant chemotherapy (p � 0.64).
3.6. Histology Subanalysis. .e most common histological
subtypes included well-diﬀerentiated liposarcoma (n� 71),
dediﬀerentiated liposarcoma (n� 69), and leiomyosarcoma
(n� 162). Diﬀerences were detected on pooled logrank
analysis for median recurrence-free survival between well-
diﬀerentiated liposarcoma (49.1months 95% CI: 26.0–72.1),
dediﬀerentiated liposarcoma (26.9months 95% CI: 12.7–
41.4), and leiomyosarcoma (25.4months 95% CI: 16.4–34.3)
(p � 0.03), as well as in median overall survival between
well-diﬀerentiated liposarcoma (142.1months 95% CI:
94.1–190.2), dediﬀerentiated liposarcoma (51.2months 95%
CI: 33.1–69.2), and leiomyosarcoma (70.8months 95% CI:
56.8–84.8) (p< 0.01).
In a further subanalysis on patients with dediﬀerentiated
liposarcoma, there was no diﬀerence detected on Chi-
squared analysis between the recurrence pattern (locore-
gional versus distant recurrence versus both) and patients
who received adjuvant radiotherapy (p � 0.58), neoadjuvant
radiotherapy (p � 0.64), neoadjuvant chemotherapy (p �
0.54), or adjuvant chemotherapy (p � 0.13). .ere was no
diﬀerence when comparing recurrence and patients who
received adjuvant radiotherapy (p � 1.00), neoadjuvant
radiotherapy (p � 1.00), neoadjuvant chemotherapy (p �
0.71), or adjuvant chemotherapy (p � 1.00). Finally, there
was no diﬀerence between overall survival in patients who
received adjuvant radiotherapy (p � 0.51), neoadjuvant
radiotherapy (p � 0.14), neoadjuvant chemotherapy (p �
0.10), or adjuvant chemotherapy (p � 1.00).
In a similar subanalysis on patients with leiomyo-
sarcomas, on Chi-squared analysis, there was no diﬀerence
in the pattern of recurrence and patients who received
neoadjuvant radiation therapy (p � 1.00), neoadjuvant
chemotherapy (p � 0.71), or adjuvant chemotherapy
(p � 0.66). Additionally, there was no diﬀerence in re-
currence in patients who received neoadjuvant radiation
(p � 0.64), adjuvant radiation (p � 0.82), neoadjuvant
chemotherapy (p � 1.00), or adjuvant chemotherapy
(p � 0.47), as well as overall survival in those who received
neoadjuvant radiotherapy (p � 0.15), adjuvant radiotherapy
(p � 0.07), or adjuvant chemotherapy (p � 1.00). In those
that received adjuvant radiation therapy, there were less than
predicted patients with locoregional recurrences as com-
pared to distant metastases (0 versus 14 patients; p � 0.04).
Further, those patients which underwent neoadjuvant
chemotherapy had an increased overall survival on Chi-
squared analysis (44% versus 18% mortality; p � 0.04).
Sarcoma NOS
26 (5%)
Other sarcomas
187 (33%)
Leiomyosarcoma
162 (28%)
Liposarcoma
196 (34%)
Figure 1: Pie chart demonstrating proportion of diﬀerent histo-
logical subtypes.
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Figure 2: Kaplan–Meier curves for disease-free and overall survival
demonstrating median survival of 35.3months (95% CI: 27.6–43.0)
and a 1-, 5-, and 10-year overall survival of 86.2%, 64.3%, and
58.7%, respectively, with associated number at risk for each time
point.
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However, when accounting for factors previously shown to
be important predictors of overall survival (Figure 4), in-
cluding age, tumor grade, nodal status, presence of multi-
focal disease, degree of multivisceral resection, and margin
status, neoadjuvant chemotherapy was not found to be an
independent predictor of overall survival on multivariate
logistical regression analysis (p � 0.08; OR� 3.83; 95% CI:
0.84–17.5).
3.7. Chemotherapy and Radiation #erapy Analysis. A total
of 12.3% (n� 70) patients underwent neoadjuvant radiation
therapy, 15.6% (n� 89) underwent neoadjuvant chemother-
apy, and 16.3% (n� 93) underwent adjuvant chemotherapy.
On univariate analysis, recurrence was not signiﬁcantly dif-
ferent between patients receiving neoadjuvant radiation
therapy (p � 0.69), neoadjuvant chemotherapy (p � 0.35), or
adjuvant chemotherapy (p � 0.20).
Disease-free survival
Hazard ratio (HR) and 95% CI
Factor
High-grade tumors
Nodal disease
Tumors 10–20cm
compared to <10cm
Tumors >20cm
compared to <10cm
Multivisceral resection
with 1-2 organs vs. 0
Multivisceral resection
with 2–4 organs vs. 0
Multivisceral resection
with ≥5 organs vs. 0
R1
R2
0 6
Figure 3: Forest plot demonstrating the hazard ratios and associated 95% conﬁdence intervals for each factor included in the multivariate
Cox proportional hazards model for disease-free survival.
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Hazard ratio (HR) and 95% CI
Overall survival
Factor
Age >65
High-grade tumors
Nodal positive disease
Multifocal disease
Multivisceral resection
with 1-2 organs vs. 0
Multivisceral resection
with 2–4 organs vs. 0
Multivisceral resection
with ≥5 organs vs. 0
Radiation therapy
Chemotherapy
Radiation and chemotherapy
R1
R2
Figure 4: Forest plot demonstrating the hazard ratios and associated 95% conﬁdence intervals for each factor included in the multivariate
Cox proportional hazards model for overall survival.
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Survival was not signiﬁcantly diﬀerent between patients
receiving neoadjuvant radiation therapy (p � 1.00), adju-
vant radiation therapy (p � 0.56), neoadjuvant chemo-
therapy (p � 0.88), or adjuvant chemotherapy (p � 0.65).
Chemotherapy and radiation therapy practices did not
change across time when examined in 3-year increments
(e.g., 2000–2003) for neoadjuvant radiation therapy
(p � 0.23), adjuvant radiation therapy (p � 0.59), neo-
adjuvant chemotherapy (p � 0.11), or adjuvant chemo-
therapy (p � 0.27). A total of 6.7% of patients (n� 38)
underwent intraoperative radiation therapy (IORT). On
Chi-squared analysis, there were no diﬀerences in rates of
positive margins (p � 0.40), recurrence patterns (locore-
gional versus distant versus both; p � 0.67), or recurrence-
free survival (p � 1.00). Of those who received neoadjuvant
radiation, there was no diﬀerence in the postoperative
margin status (p � 0.18).
4. Discussion
Retroperitoneal sarcomas (RPS) represent a small subset of
all soft-tissue sarcomas [1]. In addition, there are numerous
histiotypes, making these tumors a challenge to study,
frequently without the sample size ﬁt to draw substantial
conclusions. .is is problematic as RPS tend to present at
late stages, with large tumor size and frequent recurrence
(greater than 90% recurrence at 10 years has been reported)
[17]. .erefore, an updated, multi-institutional study is
useful to determine factors associated with survival and
recurrence to better counsel patients on the risks and on-
cologic outcomes associated with resection of RPS. Our
results demonstrate that tumor-speciﬁc factors are more
associated with survival outcomes in RPS than patient- or
provider-speciﬁc factors.
.is contemporary study represents over 500 patients
with primary RPS at 8 US tertiary referral centres with long-
term follow-up, making this the largest multi-institutional
North American study available for interpretation. A par-
ticular strength of this study, not possible with many large-
scale administrative or registry databases, is the inclusion of
recurrence data (in addition to our overall survival analysis).
Disease-free survival was found to be a median of
35.3months, while median overall survival was found to be
81.6months, respectively. .ese data are comparable, or
more favorable, to other large retrospective series or large
database analyses [18, 19]. Distant recurrence was found to
occur in a signiﬁcantly shorter time interval (16.4months)
than either locoregional (25.4months) or combined distant/
locoregional (36.4months).
High-grade tumors have been consistently shown to be a
predictor of mortality and recurrence, with well-
diﬀerentiated tumors of the same histiotype shown to
have better long-term outcomes [5]. .is has been re-
producible and emphasizes its use in TNM staging, where
grade has persisted despite recent updates in the AJCC
staging system [20]. .e number of patients in this cohort
with high-grade tumors was 57%, matching the typical 2 :1
high-grade to low-grade ratio described in prior studies [1].
.e Transatlantic Working Group (TAWG) has taken this
evidence so far as to recommend core-needle biopsies prior
to resection to determine molecular subtype/grade when
imaging is not pathognomonic [21].
Soft-tissue sarcomas are classically described as traveling
hematogenously; however, a small proportion of tumors do
metastasize to lymph nodes [1]. Our data show that 4% of
patients have nodal metastases, found to be an independent
predictor of both recurrence and mortality [5]. .is is
consistent with prior reports; these patients had a 2-fold
incidence of recurrence and a 2.5-fold incidence of mor-
tality. In total, 35% of those found with nodal disease were
leiomyosarcoma, with the rest comprising numerous other
histiotypes. However, despite the larger proportion of
leiomyosarcoma seen with N1 disease, they still represent
only 8 out of 157 cases. .erefore, this report and other
reports of nodal signiﬁcance are not likely to prompt pro-
phylactic nodal dissections—or even sentinel lymph node
biopsy—for sarcoma due to the rarity of its occurrence, but
should be recognized on preoperative imaging and poten-
tially sampled, if present, for risk stratiﬁcation.
.e goals of primary oncologic resection of retroper-
itoneal sarcomas are to achieve a complete resection of the
tumor. However, these tumors present with an average size
of approximately 12–23 cm [9, 22]. In this study, multifocal
tumors contributed to worse overall survival. Additionally,
multivisceral resections likewise decreased disease-free
survival. Historically, the belief was that survival is de-
pendent on obtaining at least an R1 resection, with some
reports of improved overall survival with R0 as compared
to R1 resection [6]. Our study corroborates prior ﬁndings
that grossly positive margins (R2) were associated with
decreased overall survival. .erefore, attempts to achieve a
complete macroscopic resection should be striven for,
when possible, recognizing that margins are one of the
most modiﬁable factors associated with survival (HR-
2.48). However, it should also be recognized that a R2
resection is oftentimes a surrogate for more aggressive
tumor biology.
Klooster et al. found that those patients with an R2
resection tended to have decreased overall survival but that a
subset did survive greater than 5 years [10], and that che-
motherapy, but not radiation therapy, may have had a
beneﬁcial eﬀect during the ﬁrst three years following re-
section. Conversely, our study found no evidence for ben-
eﬁcial eﬀects from either neoadjuvant or adjuvant
chemotherapy on bi- and multivariate survival outcomes.
On subgroup analysis of patients with leiomyosarcoma,
neoadjuvant chemotherapy was associated with increased
overall survival. However, it was not found to be signiﬁcant
on multivariate logistical regression analysis. In fact, for the
entire cohort, chemotherapy was associated with worse
overall survival (HR: 2.65) on Cox proportional hazards
analysis..is likely represents the histiotype of tumors being
treated with chemotherapy. .e absence of beneﬁt is con-
sistent with other prior studies; however, recent high-quality
prospective cohort studies and randomized control trials
have shown some beneﬁts to local recurrence-free and
overall survival with both radiation therapy and neoadjuvant
chemotherapy [12, 13, 19, 23, 24].
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Radiation therapy has been also suggested to decreased
locoregional recurrence. In a recent Transatlantic Retro-
peritoneal Working Group study of both well-diﬀerentiated
and dediﬀerentiated liposarcoma, perioperative radiation
therapy was associated with decreased locoregional re-
currence on univariate but not multivariate analysis [25]. In
a systematic review by Cheng et al., although radiation
therapy was associated with a relatively favorable toxicity
proﬁle, some studies demonstrated a beneﬁt on local re-
currence and R0 resection rates which indirectly resulted in
increased overall survival, while others did not [26]. In the
univariate subanalysis of patients with leiomyosarcoma,
rates of locoregional recurrence were decreased following
adjuvant radiation therapy. However, on additional uni-
variate analysis, postoperative margin status was not aﬀected
by neoadjuvant radiation therapy.
Diﬀerences in the studies described may be a reﬂection
of retrospective studies mirroring practice as compared to
controlled clinical trials. It will likely take time for retro-
spective studies to show the beneﬁts described in clinical
trials, if indeed those beneﬁts are proven to be eﬀective,
rather than just eﬃcacious. Interestingly, analysis of disease-
free and overall survival across time shows that short-term
(1 year) outcomes do not diﬀer, suggesting therapies have
not signiﬁcantly changed short-term outcomes in clinical
practice over the past 15 years. Additionally, we found that
despite increasing interest in both neoadjuvant and radia-
tion therapy in combined multimodal treatment, there have
been no diﬀerences in utilization of chemotherapy or ra-
diation therapy in this cohort. .is trend could be explained
by the relative rarity of these tumors and the poor historical
outcomes associated with treatment of retroperitoneal
sarcomas.
Despite its merits, there are limitations with our study.
.is retrospective cohort analysis over a long time period,
with its inherent selection bias, has allowed for meaningful
accrual of data but also represents a relatively heterogeneous
group of tumor subtypes. Approximately one-third of pa-
tients had one of any number of less common retroperi-
toneal tumor histiotypes. .is issue has been pervasive
throughout the study of sarcomas and likely acts to limit the
total sample size of these rare tumors, limiting statistical
power. Unfortunately, it is unlikely that accrual of high-
quality, level-one evidence addressing speciﬁc sarcoma
histiotypes is possible, primarily due to the rarity of these
tumors when considered as speciﬁc tumor types.
Finally, the rarity of sarcomas also requires pooling of
data to include enough patients to draw meaningful con-
clusions, and institutional practice variability (e.g., timing of
resection, use of locoregional, and systemic therapies) cer-
tainly exists despite having a similar patient pool. Some of
this eﬀect may be mitigated by including a large group of
practices, and investigating diﬀerences between practice
patterns as it relates to survival outcomes will be a project
that could be studied in the future.
Sarcomas are a diverse and relatively rare tumor type in
adults, often presenting as large masses with local invasion
into surrounding structures, with complete surgical re-
section (R0/R1) the mainstay of treatment. Here, with a
multi-institutional experience of resected RPS, we have
shown that tumor-speciﬁc factors contribute more than
patient-speciﬁc factors for both overall and disease-free
survival. Additionally, nonsurgical therapies, such as che-
motherapy and radiation therapy, seem to have no associ-
ation with increased survival in our cohort. .is appears to
be a sustained trend across time. Further study using
histiotype-speciﬁc databases should be developed to de-
termine optimal treatment patterns for various retroperi-
toneal sarcomas.
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